
WHAT IS CLAIMED IS:

- A therapeutic agent for treating diseases associated with an increase in radiation resistance or drug resistance of a cell, said agent comprising 5'-TCCATGGTGCTCACT-3' (SEQ ID NO:3) wherein said agent reduces radiation resistance or drug resistance of said cell.
 - 2. The therapeutic agent of claim 1 wherein said agent reduces drug resistance of said cell and further wherein said drug resistance is a resistance to a chemotherapeutic agent.
- A method for reducing radiation or drug resistance of a cell which does not overexpress *HER-2*, said method comprising introducing into said cell an antisense nucleic acid comprising a segment complementary to *HER-2* in an amount effective to reduce said radiation or drug resistance.
- 4. The method of claim 3 wherein said cell is a carcinoma cell selected from the group consisting of breast, bladder, prostate, head, neck, lung, colon, pancreas, cervical, ovarian, melanoma and stomach carcinoma cells.
- 5. The method of claim 3 wherein said antisense nucleic acid is introduced by association with a targeted liposome.
- 6. The method of claim 3 wherein said antisense nucleic acid comprises SEQ ID NO:3.
- A method for treating a person with a disease wherein said person is resistant to radiation or drug treatment of said disease, wherein resistance to said radiation or drug treatment



- 9. The method of claim 8 wherein said gene is *Ha-ras*.
- 10. The method of claim 8 wherein said gene is raf-1.
- 11. The method of claim 7 wherein said antisense nucleic acid comprises SEQ ID NO:3.
- A method for reducing radiation or drug resistance of a cell which overexpresses *HER-2*, said method comprising introducing into said cell an antisense nucleic acid comprising a segment complementary to *HER-2* in an amount effective to reduce said radiation or drug resistance.
- 13. The method of claim 12 wherein said cell is a carcinoma cell selected from the group consisting of breast, bladder, prostate, head, neck, lung, colon, pancreas, cervical, ovarian, melanoma and stomach carcinoma cells.
- 14. The method of claim 12 wherein said antisense nucleic acid is introduced by association with a targeted liposome.
- 15. The method of claim 16 wherein said antisense nucleic acid comprises SEQ ID NO:3.
- A method for treating a person with a disease wherein said person is resistant to radiation or drug treatment of said disease, wherein resistance to said radiation or drug treatment

- 17. The method of claim 16 wherein said resistance to radiation or drug treatment results from a mutation in or overexpression of a gene selected from the group consisting of sis (PDGF-β); trk; met; src; mos; protein kinase C β-1; ets-1; raf-1; Ha-ras; c-Fos; c-Jun; c-myc; Shc; Grb2; Sos; PLC_γ; and a gene encoding ERK1, ERK2, MEKK, MEK1, MEK2, MAPK, SAPK, MAP2, MAP4, TNF-α receptor, EGF receptor, PKC-α, PC-PLC, PKC-ε, an RTK, a TCR-CD3, an STMR, a PTKs, or a G protein.
- 18. The method of claim 17 wherein said gene is *Ha-ras*.
- 19. The method of claim 17 wherein said gene is *raf-1*.
- 20. The method of claim 16 wherein said antisense nucleic acid comprises SEQ ID NO:3.

add A2